Clovis looks to prostate cancer to differentiate its PARP blocker - CEO interview

19 October 2018

While PARP blocker rivals AstraZeneca (LSE: AZN) and Tesaro (Nasdaq: TSRO) chase the prize of a first-line ovarian cancer indication, Clovis Oncology (Nasdaq: CLVS) is highlighting what it sees as promising prostate cancer data at this year’s ESMO congress.

However, chief executive Patrick Mahaffy is quick to point out that his firm remains “committed to the ovarian cancer market,” with “a 1,000 patient front-line maintenance study, in combination with Opdivo (nivolumab), that is presently enrolling."

While Astra’s Lynparza (olaparib) is on a roll, with a label expansion covering this indication seemingly within reach and sales of $269 million in the first half of the year, Clovis’ option Rubraca (rucaparib) has struggled to gain traction, taking in just $42.3 million in the same period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK